Norris Medicines Limited (BOM:524414)
India · Delayed Price · Currency is INR 18.70
-0.97 (-4.93%)
At close: Sep 25, 2026
Norris Medicines Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 0.22 | 0.4 | 0.38 | 0.2 | 0.19 |
Cash & Short-Term Investments | 0.22 | 0.22 | 0.4 | 0.38 | 0.2 | 0.19 |
Cash Growth | -45.73% | -45.72% | 5.87% | 84.82% | 9.12% | -10.08% |
Accounts Receivable | - | 11.74 | 14.09 | 10.61 | 11 | 10.92 |
Receivables | - | 11.74 | 14.09 | 17.72 | 11 | 10.92 |
Inventory | - | 39.84 | 41.28 | 43.34 | 32.05 | 24.26 |
Prepaid Expenses | - | 0.17 | 0.24 | - | - | 0.38 |
Other Current Assets | - | 6.16 | 7.43 | - | 5.95 | 6.98 |
Total Current Assets | - | 58.13 | 63.43 | 61.43 | 49.2 | 42.73 |
Property, Plant & Equipment | - | 47.87 | 52.68 | 57.86 | 64.69 | 70.69 |
Long-Term Investments | - | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
Long-Term Deferred Tax Assets | - | 9.04 | 9.04 | 9.63 | 10.52 | 16.09 |
Other Long-Term Assets | - | 12.7 | 12.66 | 0 | 12.32 | 12.27 |
Total Assets | - | 128.89 | 138.1 | 141.87 | 136.86 | 141.91 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | 26.22 | 30.25 | 17.76 | 13.8 | 13.25 |
Accrued Expenses | - | 32.02 | 31.64 | 30.57 | 29.83 | 22.51 |
Short-Term Debt | - | 30.23 | 30.53 | 29.32 | 29.79 | 29.76 |
Other Current Liabilities | - | 6.79 | 9.07 | 14.6 | 3.62 | 2.31 |
Total Current Liabilities | - | 95.25 | 101.5 | 92.26 | 77.05 | 67.84 |
Long-Term Debt | - | 185.12 | 185.27 | 185.92 | 184.25 | 181.01 |
Other Long-Term Liabilities | - | - | 0 | 0 | - | 0 |
Total Liabilities | - | 280.38 | 286.77 | 278.17 | 261.3 | 248.85 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 99.26 | 99.26 | 99.26 | 99.26 | 99.26 |
Retained Earnings | - | -250.74 | -247.93 | -235.56 | -223.69 | -206.2 |
Comprehensive Income & Other | - | - | - | 0 | - | - |
Shareholders' Equity | -151.48 | -151.48 | -148.68 | -136.3 | -124.43 | -106.94 |
Total Liabilities & Equity | - | 128.89 | 138.1 | 141.87 | 136.86 | 141.91 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 215.35 | 215.35 | 215.8 | 215.24 | 214.04 | 210.77 |
Net Cash (Debt) | -215.14 | -215.14 | -215.41 | -214.86 | -213.84 | -210.58 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -21.52 | -21.51 | -21.54 | -21.48 | -21.38 | -21.06 |
Filing Date Shares Outstanding | 9.92 | 10 | 10 | 10 | 10 | 10 |
Total Common Shares Outstanding | 9.92 | 10 | 10 | 10 | 10 | 10 |
Working Capital | - | -37.13 | -38.07 | -30.83 | -27.84 | -25.11 |
Book Value Per Share | -14.97 | -15.15 | -14.87 | -13.63 | -12.44 | -10.69 |
Tangible Book Value | -151.48 | -151.48 | -148.68 | -136.3 | -124.43 | -106.94 |
Tangible Book Value Per Share | -14.97 | -15.15 | -14.87 | -13.63 | -12.44 | -10.69 |
Land | - | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 |
Buildings | - | 58.5 | 58.5 | 58.5 | 58.5 | 58.5 |
Machinery | - | 213.36 | 213.27 | 213.08 | 215.2 | 214.9 |